Brainstorm Cell Therapeutics, Inc. (BCLI)
0.98
-0.08
(-7.55%)
USD |
OTCM |
Aug 21, 16:00
Brainstorm Cell Therapeutics Debt to Equity Ratio : -0.1185 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1185 |
| March 31, 2026 | -0.1352 |
| December 31, 2025 | -0.1177 |
| September 30, 2025 | -0.0555 |
| June 30, 2025 | -0.0953 |
| March 31, 2025 | -0.2374 |
| December 31, 2024 | -0.1314 |
| September 30, 2024 | -0.1388 |
| June 30, 2024 | -0.2728 |
| March 31, 2024 | -0.202 |
| December 31, 2023 | -0.2625 |
| September 30, 2023 | -1.120 |
| June 30, 2023 | -0.848 |
| March 31, 2023 | -0.7601 |
| December 31, 2022 | -1.358 |
| September 30, 2022 | 3.154 |
| June 30, 2022 | 0.604 |
| March 31, 2022 | 0.3839 |
| December 31, 2021 | 0.2626 |
| September 30, 2021 | 0.2207 |
| June 30, 2021 | 0.2002 |
| March 31, 2021 | 0.1789 |
| December 31, 2020 | 0.2035 |
| September 30, 2020 | 0.0577 |
| June 30, 2020 | 0.1815 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.2237 |
| December 31, 2019 | -0.1936 |
| September 30, 2019 | -0.3881 |
| June 30, 2019 | -0.6282 |
| March 31, 2019 | 9.340 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| NovelStem International Corp. | -0.8748 |
| Summit Therapeutics, Inc. | 0.0324 |
| Kezar Life Sciences, Inc. | 0.0208 |
| Protara Therapeutics, Inc. | 0.017 |
| Clene, Inc. | -0.9018 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 0.788M |
| Total Liabilities (Quarterly) | 12.38M |
| Shareholders Equity (Quarterly) | -11.60M |
| Current Ratio | 0.0255 |
| Net Debt Paydown Yield | 0.72% |